United States Cephalosporin Drugs Market 2025: Industry Developments, Future Growth, Share & Insights |Astellas Pharma Inc., Baxter International, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC

The global cephalosporin drugs market reached US$ 14.1 billion in 2022 and is expected to reach US$ 17.8 billion by 2031, growing at a CAGR of 2.6% from 2024 to 2031, according to DataM Intelligence.

United States: Recent Industry Developments
October 2025
✅ Shionogi received FDA approval for cefiderocol expanded label in hospital-acquired pneumonia (HAP/VAP) caused by MDR Gram-negatives.The update strengthens Fetroja's position as a last-line therapy in ICU settings.It solidifies Shionogi's leadership in siderophore cephalosporins.

September 2025
✅ Lupin launched generic ceftaroline fosamil (Teflaro) in the U.S., offering 40% cost savings vs. branded.The injectable targets community-acquired pneumonia and skin infections.This entry intensifies generic competition in the fifth-generation segment.

August 2025
✅ Merck expanded U.S. production of cefepime-tazobactam combination to counter rising ESBL infections.The investment ensures supply resilience amid global API volatility.

It reinforces Merck's dominance in hospital injectables.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):
https://www.datamintelligence.com/download-sample/cephalosporin-drugs-market?sindhuri

Japan: Recent Industry Developments
October 2025
✅ Shionogi initiated Phase 3 trials for oral cefiderocol prodrug targeting outpatient MDR infections.The program aims to reduce hospital stays and IV dependency.It positions Japan as a hub for next-gen oral cephalosporin innovation.

September 2025
✅ Astellas received PMDA approval for ceftobiprole in complicated skin infections.The fifth-generation agent fills a gap in MRSA coverage for Japanese hospitals.This approval expands Astellas' anti-infective franchise.

August 2025
✅ Teva Japan launched generic cefepime injection with improved stability profile.The product targets surgical prophylaxis and febrile neutropenia.It strengthens Teva's leadership in affordable hospital generics.

Asia-Pacific: Recent Industry Developments
October 2025
✅ Macleods Pharmaceuticals commissioned a dedicated cephalosporin injectable facility in India, capacity 50M vials/year.The USFDA-approved plant targets U.S. and EU exports.This expansion cements India's role as the global cephalosporin API powerhouse.

September 2025
✅ Sandoz (Novartis) launched ceftazidime-avibactam in China via priority review pathway.The combination addresses CRE infections in tertiary hospitals.It accelerates Sandoz's penetration in high-burden AMR markets.

August 2025
✅ Pfizer partnered with a South Korean CDMO to produce cefiderocol for ASEAN markets.The collaboration ensures regional supply amid rising MDR prevalence. This move strengthens Pfizer's foothold in Asia-Pacific critical care.

Market Trends & Drivers
The Global Cephalosporin Drugs Market is sustained by persistent infectious disease burden, surgical prophylaxis, and generic dominance in emerging markets. Key trends include shift to fifth-generation agents (cefiderocol, ceftaroline), combination therapies with β-lactamase inhibitors, and stewardship programs to preserve efficacy. AMR surveillance, hospital consolidation, and complex injectable barriers delay full genericization. Challenges include resistance emergence, regulatory hurdles for new indications, and supply chain concentration in India/China. Opportunities lie in oral switch therapy, pediatric formulations, and outpatient parenteral antimicrobial therapy (OPAT).

Speak to Our Analyst and Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/cephalosporin-drugs-market?sindhuri

Competitive Landscape
1. Astellas Pharma Inc. focuses on innovative diabetes and metabolic disorder therapies, leveraging its advanced research in GLP-1 receptor agonists and strategic collaborations to expand its presence in the oral anti-diabetic drug market.

2. Baxter International Inc. strengthens its position through renal and metabolic care solutions, integrating oral anti-diabetic support within its chronic disease management portfolio to enhance patient outcomes.

3. F. Hoffmann-La Roche AG advances precision medicine in diabetes management, investing in biomarker-driven R&D and companion diagnostics to support safer, more personalized oral therapy approaches.

4. GlaxoSmithKline PLC (GSK) builds on its metabolic research heritage, developing novel small-molecule oral agents and strategic partnerships to re-enter the diabetes therapeutics market with improved formulations.

5. Lupin Pharmaceuticals Ltd. leads in affordable oral anti-diabetic generics, including metformin, DPP-4 inhibitors, and FDCs, supported by strong manufacturing capabilities and a growing presence in the U.S. and emerging markets.

6. Macleods Pharmaceuticals Ltd. excels in cost-effective generic production of oral diabetes drugs across Asia, Africa, and Latin America, with expanding R&D capabilities in novel combinations and sustained-release formulations.

7. Mankind Pharma Ltd. dominates the Indian oral diabetes drug market with high-quality, affordable generics and aggressive marketing strategies, expanding its therapeutic footprint across Tier-II and Tier-III cities.

8. Merck & Co., Inc. (MSD) remains a global leader in oral diabetes care with its Januvia® and Janumet® DPP-4 inhibitor franchise, while advancing pipeline innovations in combination and long-acting oral agents.

9. Novartis International AG strengthens its diabetes portfolio through Galvus® (vildagliptin) and combination therapies, emphasizing clinical outcomes in metabolic and cardiovascular risk management.

10. Teva Pharmaceuticals Industries Ltd. leads in high-volume generic oral diabetes drug manufacturing, ensuring global supply security while investing in improved formulations and affordability-driven innovation.

11. Shionogi & Co., Ltd. advances novel small-molecule approaches for metabolic disorders, focusing on next-generation oral therapies that target insulin resistance and glucose regulation with enhanced safety profiles.

Buy now and enjoy a 30% year-end discount - limited-time offer!
https://www.datamintelligence.com/buy-now-page?report=cephalosporin-drugs-market?sindhuri
(Purchase 2 or more Reports and get 50% Discount)

Segmentation
By Type
The Global Cephalosporin Drugs Market is segmented into Generic Cephalosporin Drugs and Branded Cephalosporin Drugs. Generic variants dominate due to their affordability and widespread availability, while branded drugs maintain strong presence in developed markets driven by trust and brand recognition.

By Generation
Based on generation, the market includes First-, Second-, Third-, Fourth-, and Fifth-generation Cephalosporins. Third- and Fourth-generation drugs hold a major share for their broad-spectrum antibacterial activity, whereas Fifth-generation cephalosporins are gaining traction for treating resistant bacterial infections.

By Formulation
The market is categorized by formulation into Injection and Oral forms. Injectable cephalosporins are preferred in hospital settings for severe infections, while oral formulations are commonly prescribed for outpatient treatment due to ease of administration.

By Indication
Cephalosporin drugs are used to treat a wide range of infections including Respiratory Tract Infection, Skin Infection, Ear Infection, Bacterial Infection, Urinary Tract Infection, Sexually Transmitted Infection, Sinus Infection, Surgical Prophylaxis, and others. Their versatility across indications continues to drive clinical adoption globally.

By Distribution Channel
Distribution of cephalosporin drugs occurs through Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies. Hospital pharmacies remain the leading channel due to prescription-based sales, while online platforms are rapidly emerging with improved access to antibiotics.

Regional Analysis

The Cephalosporin Drugs Market is segmented into North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North America leads with advanced healthcare systems and strong R&D activity among major pharmaceutical companies.

Europe holds a significant share driven by high antibiotic usage and robust infection management protocols. Meanwhile, the Asia Pacific region is expected to register the fastest growth owing to rising bacterial infection rates, expanding healthcare infrastructure, and increasing antibiotic demand.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription
✅ Competitive Landscape
✅ AMR Surveillance & Resistance Trends
✅ Pipeline Combination Therapies
✅ Generic Entry & Price Erosion Analysis
✅ Hospital Formulary Inclusion Metrics
✅ API Supply Chain Dynamics
✅ Live Pricing & Reimbursement Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us:
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us:
DataM Intelligence is a full-service market research and consulting firm, guiding organizations from initial insight to strategic implementation. We transform proprietary data, emerging trends, and market developments into agile, actionable solutions.
Our robust methodology powers a vast research database featuring 6,300+ syndicated and custom reports across 40+ industries. We have delivered strategic solutions to 200+ companies in 50+ countries, addressing the core research challenges that drive growth for our clients.

This release was published on openPR.